CureVac’s Final Chapter: Shareholders Seal Merger Fate
03.12.2025 - 07:07:04 | boerse-global.de
A significant deadline has arrived for one of Germany’s most closely watched biotech narratives. The offer period for BioNTech’s exchange tender concludes today, marking the irreversible end of CureVac’s journey as an independent publicly traded entity. For investors still holding shares, this final cutoff carries specific implications, while the path toward an inevitable delisting from public markets is now clear.
The direct consequence for CureVac’s equity is its imminent disappearance from the Nasdaq exchange. Following the approved legal merger, CureVac will effectively be absorbed into a new entity or integrated wholly, allowing BioNTech to consolidate the mRNA technology platform without the operational overhead of a separate listed company. Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
